INTRODUCTION
============

Augmentation cystoplasty (AC) is a definitive surgical procedure used in adult and children with refractory bladder dysfunction, including a small bladder capacity and inadequate bladder compliance, and in whom all conservative and medical treatments have failed \[[@b1-inj-1836174-087]\]. The main objective of this procedure is to create a low-pressure reservoir bladder, in an attempt to preserve kidney function, achieve satisfactory continence, and improve quality of life. AC is considered to be the gold standard for refractory bladder dysfunction of either neurogenic or nonneurogenic etiology \[[@b2-inj-1836174-087]-[@b4-inj-1836174-087]\]. A difficulty, however, occurs when the intestinal segments used for the augmentation come into contact with urinary tissue. As these epithelial issues are functionally different, numerous complications can arise when they come into contact, including recurrent urinary tract infections (UTIs), urolithiasis, metabolic imbalance, bladder perforation, and the potential for malignancy. As these complications threaten long-term health and survival, long-term follow-up and surveillance are needed. However, few studies have analyzed the long-term follow-up of patients whose bladders were augmented with intestinal tissue during childhood \[[@b5-inj-1836174-087]-[@b8-inj-1836174-087]\].

Our review of the literature indicated that controversies still exist regarding the long-term complications of using intestinal segments for bladder augmentation in children, including the potential for malignancy, metabolic imbalances leading to linear growth retardation, and deterioration in renal function following AC. Although a few studies have proposed that AC adversely affects linear growth in children, especially in patients with bladder exstrophy \[[@b9-inj-1836174-087],[@b10-inj-1836174-087]\], other studies, comparing children who had undergone AC to a control group matched by age, sex, level of defect, and ambulatory status, did not identify an effect of AC on growth, bone density, or height percentile \[[@b11-inj-1836174-087],[@b12-inj-1836174-087]\].

Moreover, the risk of carcinogenesis at the vesicointestinal junction following AC has not been well defined. However, concerns have arisen due to some documented cases of cancer in the augmented bladder occurring many years after surgery. Based on this finding, repeated cystoscopy examinations have been proposed for long-term cancer surveillance after AC \[[@b13-inj-1836174-087]\]. Another study argued that the risk for malignancy in children who undergo AC for congenital bladder dysfunction is not specifically related to the AC procedure, but rather is an inherent risk of cancer associated with the underlying congenital abnormality \[[@b14-inj-1836174-087]\].

To date, most studies have reported short-term outcomes of AC, with longer term outcomes addressed in only a few studies. Therefore, the purpose of our study was to retrospectively analyze long-term outcomes in children with refractory bladder dysfunction who underwent AC at our center.

MATERIALS AND METHODS
=====================

Our retrospective analysis of pediatric patients with refractory bladder dysfunction who underwent AC between 2000 and 2005 was approved by our Office of Research Affairs (RAC\# 2161012). Written informed consent by the patients was waived by the Office of Research Affairs due to a retrospective nature of our study.

Inclusion and Exclusion Criteria
--------------------------------

The eligible patients were all children \<15 years old with a clinical diagnosis of a small-capacity and noncompliant bladder and in whom maximum conservative and/or minimally invasive treatment failed to provide symptom resolution and continence. Patients who did not complete a minimum 10-year follow-up, those who were lost to follow-up, and those who underwent ureterocystoplasty or had reconstructive procedures without AC were excluded.

Information on patients' demographic variables, diagnosis, surgical details, renal function, and postoperative complications was extracted from the medical records for inclusion in the analysis. All patients underwent voiding cystourethrography to confirm bladder capacity and the presence or absence of vesicoureteral reflux. Dimercaptosuccinic acid Tc-99 scintigraphy imaging was performed to document renal scarring and split renal function. Information on procedures performed prior to AC, concurrent with AC, and post-AC and complications was extracted from patients' charts. Ultrasound examination of the kidneys was completed to document the presence or absence of renal stone and hydro-ureteronephrosis. Cystoscopy was performed immediately before AC to document any lower urinary tract pathology and to confirm bladder capacity. Height, weight, and serum biochemistry levels (calcium, phosphate, chloride, and carbon dioxide) were recorded before AC and at the last follow-up of each patient. Height and weight were compared to the 2000 standardized values from the Centers for Disease Control and Prevention (CDC), matched by age and sex.

Surgical Procedures
-------------------

Enterocystoplasty was performed using a technique described by Mundy and Stephenson \[[@b15-inj-1836174-087]\]. Cystography was performed on postoperative day 14, and the catheter was removed if no extravasation was observed. Patients were instructed to perform clean intermittent catheterization (CIC) and to maintain a vigorous irrigation protocol over the first year postsurgery to prevent mucus accumulation. Irrigation was performed, thereafter, when patients noticed mucus in their urine. Concomitant procedures performed at the time of AC were Mitrofanoff channel creation, Malone antegrade continent enema (MACE), bilateral or unilateral ureteral reimplantation, bladder neck procedures, and simple nephrectomy.

Follow-up
---------

Patients were followed-up at 6 weeks postoperatively, then every 6 months for 2 years, and then annually until 14 years of age, after which patients were referred to our adult urology colleagues for further follow-up. Patients were assessed for renal profile, blood biochemistry levels, anthropometric measurements (height and weight), and ultrasound of the kidneys and bladder at each follow-up visit. Bladder capacity was assessed preoperatively and postoperatively by a functional voiding volume diary, as well as clinical and radiological assessments. Urine cytology and cystoscopy were scheduled at 10 years post-AC or upon the occurrence of microscopic or gross hematuria. Urodynamic studies were performed in selected cases with renal function deterioration, new-onset hydronephrosis, or worsening of upper tract dilatation and reflux.

Statistical Analysis
--------------------

Demographic and clinical variables were measured preoperatively and postoperatively, with between-group differences evaluated using the Student t-test. To control for effects of height and weight at baseline, patients were categorized into 3 percentile subgroups (\<50th, 50th--75th, and \>75th percentile), based on the CDC growth scale evaluated using the Student t-test. The paired t-test was used to evaluate longitudinal changes in the measured variables. All analyses were performed using IBM SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

Between January 2000 and December 2005, 59 patients with refractory bladder dysfunction underwent AC, of whom 42 met our inclusion criteria. The relevant demographic and surgical variables are summarized in [Table 1](#t1-inj-1836174-087){ref-type="table"}. The mean age at the time of AC was 8.4±5.2 years, with a median follow-up duration after AC of 12.0±1.5 years and a median age at the time of the last follow-up of 19.4±4.4 years. All patients underwent AC using the ileum with or without a continent outflow procedure. Among our study group, 28 patients (66.7%) had a diagnosis of neurogenic primary lower urinary tract dysfunction, with the other 14 (33.3%) having a nonneurogenic diagnosis, including bladder exstrophy in 7 (16.7%), posterior urethral valves (PUVs) in 4 (9.5%) patients, and cloacal abnormality, cystinosis, and rhabdomyosarcoma in 1 patient each.

All patients were incontinent, with varying degrees of severity. Twenty-one patients (50.0%) underwent procedures before proceeding to AC, which included bladder exstrophy repair in 7 patients, vesicostomy in 5 patients, dextranomer/hyaluronic acid injection in 4 patients, bladder neck procedures in 2 patients, and Mitrofanoff channel creation, partial cystectomy, and nephrectomy in 1 patient each.

During AC, 50% of the patients had various concurrent procedures. A Mitrofanoff continent outflow channel was created in 10 patients (23.8%). MACE was performed in 6 patients (14.3%). Concurrent procedures with AC are shown as a bar chart in [Fig. 1](#f1-inj-1836174-087){ref-type="fig"}.

Renal function remained stable or improved in 32 patients (76.2%), and deterioration of renal function was observed in 4 patients (9.5%). Among these latter 4 cases, PUVs were the etiology of bladder dysfunction in 3 cases. Six patients (14.3%) had end-stage renal disease (ESRD) (3 cases of PUV, 2 cases of myelomeningocele, and 1 case of cloacal exstrophy), and had pretransplant AC.

Among all patients, there were no significant preoperativeto-postoperative changes in serum levels of the biochemical parameters measured to assess metabolic acidosis and/or bone metabolism (calcium, phosphate, chloride, and blood CO~2~). These biochemical values were noted just before AC and at last the follow-up from patients' electronic records. Bladder capacity was measured before AC and at 1 year post-AC with a cystogram. However, bladder capacity and body height and weight significantly increased after AC, as represented in [Table 2](#t2-inj-1836174-087){ref-type="table"}.

Regarding height and weight, we included 32 patients who had stabilized renal function in order to remove the effect of confounding factor of metabolic acidosis due to ESRD on height and weight. We obtained height and weight measurements pre-AC and at the last follow-up. Controlling for height and weight, no significant difference was found before and after AC in the distribution of patients across the 3 percentile groups for height and weight (\<50th, 50th--75th, and \>75th percentiles of CDC growth values) ([Tables 3](#t3-inj-1836174-087){ref-type="table"}, [4](#t4-inj-1836174-087){ref-type="table"}, respectively).

Complications arising \>1 year post-AC were considered to be long-term complications. Thirty-seven patients (88.1%) were continent after a follow-up of 12.0±1.5 years. Five patients (11.9%) required a bladder neck procedure in the form of bladder neck reconstruction in 2 patients, bladder neck suspension in 1 patient, and endoscopic bladder neck injection with dextranomer/hyaluronic acid in 2 patients for continence. Four patients (9.5%) underwent cystolithotomy for bladder stone, of whom 3 underwent cystolithotomy twice and 1 underwent cystolithotomy 3 times due to stone recurrence. Three patients (7.1%) developed kidney stones, of whom 2 underwent extracorporeal lithotripsy and 1 underwent percutaneous nephrolithotomy. A febrile UTI developed in 12 patients, and was treated using intravenous antibiotics. We did not identify any occurrence of bladder perforation or malignancy in our case series. Postaugmentation procedures and complications are presented in [Fig. 2](#f2-inj-1836174-087){ref-type="fig"}. Thirty patients (71.4%) needed 72 additional procedures after AC. A Mitrofanoff continent channel was created in 21 of the patients (50.0%) at a median of 5.0±2.4 years post-AC. All parents were given the option of a Mitrofanoff channel at the time of the preoperative AC work-up, and we have a dedicated uro-stoma nurse for preoperative and postoperative follow-up. Initially, these patients and their parents refused. Of the 21 patients who underwent post-AC Mitrofanoff channel creation, 3 had total incontinence and underwent bladder neck closure with simultaneous Mitrofanoff channel creation. Eighteen patients independently requested the procedure after meeting other patients with a Mitrofanoff channel. Thirteen of the 18 patients had a simultaneous MACE procedure along with Mitrofanoff channel creation. Mitrofanoff revision was done in 3 (7.1%), and MACE was performed in 13 patients (31.0%) for fecal incontinence.

DISCUSSION
==========

AC is a very effective procedure in patients with refractory bladder dysfunction. Interposition of bowel tissue within the urinary bladder is used for conversion to a low-pressure and compliant bladder, while preserving the upper urinary tract, which provides continence \[[@b16-inj-1836174-087]\]. However, this procedure is not free of complications. In particular, the functional differences between the urinary and bowel epithelium have been raised as a potential risk for long-term complications, including the development of malignancy. As such, long-term follow-up of children who undergo AC is recommended for the early identification and management of complications. As these patients generally have a hypocontractile bladder after AC, CIC is used to guarantee complete bladder emptying, performed through the urethra or a continent stoma (Mitrofanoff). Usually this channel is created concomitantly with AC, particularly in patients with neurogenic bladder \[[@b17-inj-1836174-087]\]. Most patients, especially children, prefer to use a Mitrofanoff channel for CIC, rather than transurethral catheterization \[[@b18-inj-1836174-087]\].

Although AC preserves the upper urinary tract and renal function, by reducing the high-pressure intrabladder pressure, there is a theoretical risk of renal function deterioration after AC. In their 10-year follow-up of 53 patients after AC, Fontaine et al. \[[@b19-inj-1836174-087]\] reported that renal function improved or remained stable in 81% of cases, and deteriorated in 19% of cases. In our cases series, renal deterioration occurred in 4 patients (9.5%), in 3 of whom PUV and preoperative kidney dysplasia were diagnosed. We consider it likely that these pre-existing conditions contributed to the deterioration in renal function in these patients, rather than the AC. In our previously published case series of 29 adult patients, pre-existing bladder conditions (incomplete emptying, recurrent UTIs, and PUV) were identified as a significant risk factor for the deterioration of renal function after AC \[[@b20-inj-1836174-087]\].

Bladder stone formation is generally one of the most common long-term problems after AC, with an incidence of 3%--40% \[[@b21-inj-1836174-087]\]. It is generally accepted that the combination of urinary stasis, increased mucous production, noncompliance with CIC, abnormalities in urine composition, and chronic infection with urea-splitting organisms increase the risk of bladder stone formation \[[@b22-inj-1836174-087],[@b23-inj-1836174-087]\]. Among our case series, bladder stones developed in 4 patients (9.5%), with renal stones further developing in 3 patients (7.1%). Although those patients experienced recurrent stone formation, we failed to find a reasonable cause for this recurrence.

Hensle et al. \[[@b24-inj-1836174-087]\] reported that prophylactic use of a bladder irrigation protocol reduced the incidence of bladder stone formation from 43% to 7%, and that patients who performed CIC through an abdominal stoma were at a higher risk of stone formation than those who performed CIC via the native urethra (65% vs. 15%). All bladder stones in our case series were composed of magnesium ammonium triple phosphate, which is considered to be of infectious origin. In contrast, in 1 of the 3 patients who developed renal stones, the stone was composed of magnesium ammonium triple phosphate, while the stones in the other 2 patients were composed of calcium oxalate dihydrate. Szymanski et al. \[[@b25-inj-1836174-087]\] reported an incidence of bladder stones of 66% in their case series, with an infectious cause identified in almost half of these cases.

The effect of AC on linear growth and development of children after AC remains controversial. Slowed growth after AC has been attributed to metabolic acidosis, recurrent UTIs, and anemia caused by the absorption of metabolites in the augmented portion of the bladder \[[@b26-inj-1836174-087]\]. A previous study reported a 20% reduction in linear growth in children after AC with colocystoplasty \[[@b27-inj-1836174-087]\]. We did not identify any effect of AC on developmental height and weight over the long-term follow-up in our case series. Similarly, Mingin et al. \[[@b28-inj-1836174-087]\] did not report an effect of AC on linear physical growth and bone density among children with myelomeningocele and bladder exstrophy. Moreover, we also excluded patients with ESRD to rule out the negative effects of metabolic acidosis due to renal failure on the measured variables. Our exclusion criteria were supported by a previous study that reported normal renal function in children after AC, with no effects of AC on bone mineral density or serum electrolytes \[[@b29-inj-1836174-087]\].

Spontaneous perforation is an uncommon but serious complication of AC; it has an incidence of 6%--13%, and can lead to peritonitis, sepsis, and death \[[@b30-inj-1836174-087]\]. Perforation can result from overdistension or increased intravesical pressure, and is less likely to result from traumatic catheterization or chronic infection. Metcalfe et al. \[[@b31-inj-1836174-087]\] reported an increased risk of perforation with augmentation using the sigmoid colon, combined with bladder neck surgery. In contrast, the risk of perforation was lowered by the creation of a continent stoma for catheterization. Fortunately, we did not identify any occurrence of bladder perforation in our case series.

Risk of malignancy is another reported complication after AC, although there were no occurrences in our case series. Austin et al. \[[@b32-inj-1836174-087]\] reported patients with spina bifida to be at a higher risk of bladder cancer, regardless of the status of bladder augmentation. Overall, the incidence of bladder cancer after bladder augmentation is low (estimated at 1%--4.6%), with adenocarcinoma being the most prevalent type of malignancy \[[@b33-inj-1836174-087]\].

The generalizability of the findings of our study is limited by its retrospective design and by our small and diverse patient group. Reporting errors and potential bias are the main limitations of any retrospective study. Although urodynamic studies were not performed as part of our analysis, indications for AC were based on cystogram and clinical functional assessment in patients who remained incontinent despite maximum levels of anticholinergic medications and CIC. Bladder capacity was measured by cystography, before augmentation and on followup. On follow-up, urodynamic studies were performed in selected patients in whom deterioration of renal function, upper tract dilation, or incontinence was found \[[@b34-inj-1836174-087]\]. A voiding diary was used for clinical and functional assessments. Of note, we also did not perform bone densitometry to quantify bone mineral changes after AC. These measurements should be included in future prospective studies to fully clarify the risks of AC for physical growth and malignancy.

In conclusion, bladder augmentation is a safe and effective procedure, with no identified effects on physical growth post-AC. Renal function remained stable or improved in the majority of our patients over a long follow-up period. Because of the risk for potential long-term complications post-AC, lifelong surveillance is recommended until high-quality evidence is available to inform practice.
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![Concurrent procedures performed with augmentation cystoplasty. MACE, Malone antegrade continent enema; BN, bladder neck.](inj-1836174-087f1){#f1-inj-1836174-087}

![Postaugmentation procedures for complications or incontinence in children. MACE, Malone antegrade colonic enema; BN, bladder neck; ESWL, extracorporeal shock wave lithotripsy; PCNL, percutaneous nephrolithotomy; URS, ureteroscopy; AC, augmentation cystoplasty; UC, urethrocutaneous.](inj-1836174-087f2){#f2-inj-1836174-087}

###### 

Relevant demographic information and etiology of bladder pathology (n=42)

  Variable                         Value
  -------------------------------- ------------
  Sex                              
   Male                            31 (73.8)
   Female                          11 (26.2)
  Age at AC (yr)                   8.4 ± 5.2
  Age at the last follow-up (yr)   19.4 ± 4.4
  Duration of follow-up (yr)       12.0 ± 1.5
  Preoperative diagnosis           
   Neurogenic (n)                  28
    Myelomeningocele               20 (47.6)
    Sacral agenesis                7 (16.7)
    Spinal cord trauma             1 (2.4)
   Nonneurogenic (n)               14
    Bladder exstrophy              7 (16.7)
    Posterior urethral valve       4 (9.5)
    Cloacal exstrophy              1 (2.9)
    Cystinosis                     1 (2.9)
    Rhabdomyosarcoma               1 (2.9)

Values are presented as number (%) or mean±standard deviation.

AC, augmentation cystoplasty.

###### 

Preoperative-to-postoperative changes in measured variables

  Variable                    Normal range   Preoperative   Postoperative   P-value
  --------------------------- -------------- -------------- --------------- ---------
  Serum creatinine (μmol/L)   46--96         61.0 ± 28.9    73.0 ± 151.9    0.03
  Serum calcium (mmol/L)      2.1--2.6       2.3 ± 0.2      2.3 ± 0.1       0.70
  Serum phosphate (mmol/L)    1.0--1.8       1.4 ± 0.3      1.3 ± 0.4       0.61
  Carbon dioxide (mmol/L)     22.0--31.0     22.0 ± 3.4     22.0 ± 2.9      0.76
  Serum chloride (mmol/L)     98--111        103.5 ± 4.7    103.0 ± 4.4     0.34
  Bladder capacity (mL)       --             105 ± 39.5     300.0 ± 94.1    \< 0.05
  Height (cm)                 --             111.5 ± 24.8   147 ± 19.3      \< 0.05
  Weight (kg)                 --             21.0 ± 9.6     47.0 ± 18.2     \< 0.05

Values are presented as mean±standard deviation unless otherwise indicated.

###### 

Distribution of height among the percentile groups, before and after bladder augmentation

  Percentile group   Preoperative   Postoperative
  ------------------ -------------- ---------------
  \< 50th            3 (9.4)        4 (12.5)
  50th--75th         24 (75.0)      26 (81.3)
  \> 75th            5 (15.6)       2 (6.3)

Values are presented as number (%).

P=0.212, pre- vs. postaugmentation cystoplasty.

###### 

Distribution of weight among the percentile groups, before and after bladder augmentation

  Percentile group   Preoperative   Postoperative
  ------------------ -------------- ---------------
  \< 50th            3 (9.4)        2 (6.3)
  50th--75th         25 (78.1)      27 (84.4)
  \> 75th            4 (12.5)       3 (9.4)

Values are presented as number (%).

P=0.142, pre- vs. postaugmentation cystoplasty.
